AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.Top-line results from the CLL14 ...

Roche co-markets Venclexta in the US with AbbVie, with the latter selling it on its own elsewhere as Venclyxto, and the drug is a key growth product for both companies.

Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, and commercialised by AbbVie outside of ...

Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia.

RELATED: The trial win is key for AbbVie and Roche, as it backs up a conditional AML approval the FDA doled out in late 2018 based on response rates. The agency okayed Venclexta in tandem with ...

Weeks after AbbVie and Roche's blood cancer med Venclexta flopped a confirmatory trial in acute myeloid leukemia (AML), the partners hoped for a win to keep their med's chances alive.

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

Roche RHHBY announced that the FDA has granted full approval to leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC). The combination has been approved for ...

Basel, 21 November 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Venclexta® (venetoclax), in ...

Basel, 16 May 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Venclexta® (venetoclax) in combination with Gazyva ...

By Reuters December 4, 20186:13 AM UTCUpdated ago Dec 4 (Reuters) - Roche Holding AG: * NEW VENCLEXTA/VENCLYXTO DATA DEMONSTRATE DEEP RESPONSES IN TWO OF MOST COMMON TYPES OF LEUKAEMIA ...